Prosecution Insights
Last updated: November 12, 2026
Application No. 18/700,978

NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE

Non-Final OA §103
Filed
Apr 12, 2024
Priority
Sep 28, 2021 — EU 21199548.5 +1 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Psomri Holding AB
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
72%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
886 granted / 1250 resolved
+10.9% vs TC avg
Minimal +1% lift
Without
With
+1.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
93 currently pending
Career history
1321
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant's election with traverse of Group I, and species of benzamil and lactic acid, in the reply filed on July 9, 2026 is acknowledged. The traversal is on the ground(s) that there is a finite number of salt forms that are similar. This is not found persuasive because the structural element that is shared is not novel and nonobvious over the prior art. See also below. The requirement is still deemed proper and is therefore made FINAL. 3. Claims 11-14, 19 and 20 withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected subject matter. Applicant timely traversed the restriction (election) requirement in the reply filed on July 9, 2026. Priority 4. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement 5. The information disclosure statement (IDS) submitted on April 12, 2024 was in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The IDS was considered. A signed copy of form 1449 is enclosed herewith. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. 6. Claim(s) 1-10 and 15-18 is/are rejected under 35 U.S.C. 103 as being unpatentable over US 2013109856. Determining the scope and contents of the prior art US 2013109856 teaches compounds of general structure PNG media_image1.png 86 140 media_image1.png Greyscale including specific embodiments such as PNG media_image2.png 116 268 media_image2.png Greyscale (page 15, Example 11). The reference teaches both the free base and the TFA salt of the compound. The reference further teaches pharmaceutically acceptable salts, including for example, that of lactic acid. Page 7, paragraph [0187]. Ascertaining the differences between the prior art and the claims at issue The difference between US 2013109856 and Applicant’s elected species is that the reference specifically teaches the TFA salt while the elected species is directed to the lactic acid salt. Resolving the level of ordinary skill in the pertinent art and considering objective evidence present in the application indicating obviousness MPEP 2143 B provides basic requirements of prima facie case of obviousness including examples of rationale of the simple substitution of one known element for another to obtain predictable results. To reject a claim based on this rationale the following is considered below and applied to the present claims: A finding that the prior art method differs from claimed method by the substitution of some component with another component US 2013109856 does not teach specifically the elected species in combination with lactic acid. The prior art differs from the claims to the elected species by substitution of one acid for another. A finding that the substituted components and their functions were known in the art US 2013109856 teaches various interchangeable pharmaceutical acids which result in pharmaceutically acceptable salts of the claimed compounds. For this reason, the present claims are found to be prima facie obvious over the prior art. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Apr 12, 2024
Application Filed
Sep 15, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780779
CXCR6 SULFONAMIDE COMPOUNDS
3y 7m to grant Granted Nov 03, 2026
Patent 12780778
CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
3y 3m to grant Granted Nov 03, 2026
Patent 12780795
CRYSTALLINE FORM OF TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
2y 11m to grant Granted Nov 03, 2026
Patent 12778121
ACRYLATE DERIVATIVE, USE AND PRODUCTION INTERMEDIATE COMPOUND OF THE SAME
2y 3m to grant Granted Nov 03, 2026
Patent 12767631
METHOD FOR PRODUCING POLYETHER NITRILE
2y 5m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
72%
With Interview (+1.0%)
Low
PTA Risk
Based on 1250 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month